Welcome to our dedicated page for Opus Genetics SEC filings (Ticker: IRD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Opus Genetics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Opus Genetics's regulatory disclosures and financial reporting.
Opus Genetics, Inc. Chief Financial Officer Robert E. Gagnon reported an automatic sale of 7,783 shares of common stock on July 23, 2026 at a weighted average price of $2.9477 per share, in multiple trades between $2.9006 and $3.025, to satisfy tax withholding from a restricted stock unit vesting. Following this sale, he directly holds 584,375 shares.
Robert E. Gagnon filed a notice to sell common stock of Opus Genetics, Inc. under Rule 144. The planned sale covers 7,783 shares of common stock with an aggregate market value of $23,738.15, to be executed through Jefferies LLC on or after 07/23/2026 on the NASDAQ market. The filing notes that 83,000,000 shares of this class of common stock are outstanding. The shares derive from vested restricted stock units dated 01/22/2026. In the prior three months, Gagnon reported having sold 7,842 shares of Opus Genetics common stock for an aggregate value of $40,657.63 on 04/23/2026.
George Magrath filed a notice to sell restricted securities of Opus Genetics, Inc. under SEC Rule 144. The planned sale covers 9,475 shares of common stock through Jefferies LLC, with an aggregate market value of $28,898.75 and approximately 83,000,000 shares of the same class outstanding. The shares derive from vested restricted stock units that vested on January 22, 2026, and the proposed sale date is July 23, 2026. In the prior three months, 9,511 shares of Opus Genetics common stock were sold for $49,647.42.
Joseph Schachle, associated with Opus Genetics, Inc., filed to sell company common stock through Raymond James & Associates on NASDAQ. The planned sale relates to a restricted stock unit (RSU) grant vesting dated July 22, 2026, with a planned cash transaction on July 23, 2026, covering 15,625 shares. The filing also lists a prior sale of 4,697 common shares for $24,519.00 on April 23, 2026.
Inspire Pharmaceuticals, Inc. reported that insider Benjamin Yerxa filed to sell common stock under Rule 144. The planned sale involves 25,000 shares of common stock, related to an RSU grant vest dated 07/22/2026, with sales noted as occurring on 07/23/2026 through Raymond James & Associates on NASDAQ. The filing also lists a prior sale of 7,470 common shares on 04/23/2026 for an aggregate value of $39,121.00.
Opus Genetics, Inc. registers the resale of up to 2,678,570 shares of its common stock pursuant to a shelf prospectus to satisfy a contractual registration covenant.
The registration consists of 1,116,070 Purchased Shares issued at $4.48 per share and up to 1,562,500 Conversion Shares issuable upon conversion of notes (conversion price $6.72). The Company will not receive proceeds from resales. Shares outstanding were 82,565,835 as of May 31, 2026.
Opus Genetics, Inc. reported on its expanding pipeline of gene therapies for inherited retinal diseases after hosting a Research and Development Science Forum. The company highlighted five IRD programs, with four clinical data readouts expected in 2027, and said RDH12, MERTK and RHO programs are expected to enter clinical testing over the next 12 to 18 months.
Management stated that its cash runway extends into 2029 and is expected to fund multiple clinical inflection points and potential product approvals, as well as opportunities for Priority Review Vouchers. Opus Genetics’ pipeline includes seven AAV-based programs, led by OPGx-LCA5 and OPGx-BEST1, targeting severe inherited retinal disorders.
Opus Genetics, Inc. furnishes an investor presentation from its Virtual R&D Science Forum, outlining its inherited retinal disease (IRD) gene therapy strategy and pipeline. The company highlights seven AAV-based programs targeting LCA5, BEST1, RDH12, MERTK, RHO, NMNAT1 and CNGB1, with worldwide rights to all programs.
Management states Opus is fully funded into 2029 to advance five IRD clinical programs through potential product approvals and Priority Review Voucher opportunities. Key near-term milestones include a PDUFA date in October 2026 for a partnered phentolamine sNDA, BEST1 Cohort 1 three‑month results in September 2026, Phase 3 dosing for LCA5 in Q4 2026, and initial RDH12 and MERTK clinical study initiations between Q4 2026 and Q1 2027. Four clinical data readouts are expected in 2027.
The presentation details disease biology, prevalence and preclinical data for RDH12, MERTK, RHO, LCA5 and BEST1, along with patient‑reported outcomes from the OPGx‑LCA5 study showing maintained or improved visual acuity and functional vision gains in small adult and pediatric cohorts. Opus also emphasizes global IRD prevalence, strategic partnerships for trial recruitment, and a dose‑exploration, data‑driven clinical development approach.
Opus Genetics, Inc. registers up to 2,678,570 shares of Common Stock for resale by selling stockholders.
The shares consist of 1,116,070 Purchased Shares issued under a Stock Purchase and Conversion Agreement and up to 1,562,500 Conversion Shares issuable upon conversion of Notes under a Note Purchase Agreement, with a Conversion Price of $6.72 per share. The company will not receive proceeds from resales; the registration satisfies a contractual covenant and permits the selling stockholders to sell on market or by private transactions. Shares outstanding were 82,565,835 as of May 31, 2026; last reported sale price was $4.12 on June 1, 2026.